Medtronic has initiated the pivotal trial to obtain CE mark approval for its Engager transcatheter aortic valve implantation system, used to treat patients suffering from severe aortic stenosis.
The Engager transapical valve incorporates bovine tissue leaflets and a self-expanding nitinol frame, designed to facilitate accurate positioning and stability when implanted.
Go deeper with GlobalData
The 150-patient trial conducted at 11 centres will evaluate the safety and clinical performance of the new valve and delivery system.
The Engager therapy will provide physicians with a transapical valve therapy option for patients with severe aortic stenosis, while facilitating minimally invasive delivery via a catheter inserted in the apex of the heart.
Medtronic Structural Heart Business president John Liddicoat said that transapical valve delivery can be a valuable alternative for cardiac surgeons, who will want to consider various approaches for patients who are at high risk for open-heart surgery or patients suffering from peripheral artery disease.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
